What pharmacologic treatments are recommended for an adult with alcohol use disorder who has no contraindicating medical conditions, including considerations of hepatic function?

Pharmacologic Treatment for Alcohol Use Disorder

For adults with alcohol use disorder and no contraindications, acamprosate (666 mg three times daily) or naltrexone (50 mg daily oral or 380 mg monthly intramuscular) should be prescribed in combination with counseling to reduce relapse and maintain abstinence. 1

First-Line Medication Selection

The choice between acamprosate and naltrexone depends primarily on hepatic function:

Acamprosate (Preferred for Liver Disease)

• Dosing: 666 mg three times daily
• Metabolism: No hepatic metabolism; renally excreted
• Best for: Patients who have already achieved abstinence and need help maintaining it
• Evidence: Reduces withdrawal symptoms and alcohol craving; decreases relapse rate and severity when relapse occurs 2
• Safety advantage: No reported hepatotoxicity, making it the safer choice when liver function is uncertain 1
• Number needed to treat: Approximately 12 to prevent return to drinking 1

Naltrexone (Use with Caution)

• Dosing: 50 mg daily oral OR 380 mg monthly intramuscular
• Metabolism: Hepatic metabolism
• Best for: Controlling alcohol craving in patients with normal liver function
• Evidence: Lowers risk of relapse in short-term treatment 2
• Critical caveat: Can cause hepatocellular injury; not recommended in patients with alcoholic liver disease 3
• Number needed to treat: Approximately 20 1

Special Considerations and Alternative Agents

Baclofen (30-60 mg daily in divided doses)

This is the only medication with RCT evidence specifically in patients with cirrhosis, including decompensated disease 1:

• Improved total abstinence rates and decreased relapse over 1 year
• GABA-B receptor agonist with limited hepatic metabolism
• Important warning: Exclude patients with hepatic encephalopathy, as baclofen may impair mentation 1
• Consider as second-line when acamprosate is ineffective 4

Medications to Avoid

• Disulfiram: Should be avoided due to hepatotoxicity risk, despite FDA approval 3, 1, 3
• Poor tolerability and inconsistent evidence for efficacy 2

Off-Label Options (Third-Line)

When FDA-approved medications fail:

• Gabapentin (600-1,800 mg daily): No hepatic metabolism; monitor for renal dysfunction and sedation 1
• Topiramate (75-400 mg daily): Reduces heavy drinking; not extensively metabolized 1

Essential Treatment Framework

Combination with Psychosocial Treatment is Mandatory

Medications alone are insufficient. The evidence consistently shows that pharmacotherapy must be combined with:

• Cognitive-behavioral therapy (CBT)
• Motivational enhancement therapy (MET)
• Motivational interviewing
• 12-step facilitation

Integrating AUD treatment with medical care provides the best outcomes 1, though this may not be practical in all settings.

Clinical Algorithm

Step 1: Assess Liver Function

• If normal liver enzymes and no cirrhosis → Acamprosate OR Naltrexone
• If elevated liver enzymes or any liver disease → Acamprosate only
• If cirrhosis (compensated or decompensated) → Baclofen (if no encephalopathy)

Step 2: Match to Treatment Goal

• Maintaining abstinence (patient already detoxified) → Acamprosate first-line 2
• Reducing heavy drinking (patient still drinking) → Naltrexone (if liver function normal) or Baclofen 5

Step 3: Monitor and Adjust

• Acamprosate has no effect in patients who haven't achieved abstinence first 2
• If first-line agent fails after adequate trial (12 weeks minimum), switch to alternative or consider baclofen
• Recent large RCT showed no substantial benefit of acamprosate over naltrexone or intensive counseling alone 2

Critical Pitfalls to Avoid

1. Don't prescribe naltrexone without checking liver function - it causes hepatocellular injury and has never been studied in patients with alcoholic liver disease 3

2. Don't use acamprosate to initiate abstinence - it only works to maintain abstinence in already-detoxified patients 2

3. Don't prescribe medication without concurrent counseling - pharmacotherapy alone has limited efficacy; the Class I, Level A recommendation explicitly requires combination with counseling 2

4. Don't forget about baclofen in cirrhotic patients - it's the only medication with RCT evidence in this population 1

5. Recidivism rates are 67-81% over one year 2 - set realistic expectations and plan for long-term follow-up

Strength of Evidence

The 2020 AASLD Practice Guidance 1 represents the most recent and authoritative guideline, superseding the 2012 EASL 3 and 2010 Hepatology 2 guidelines. All consistently recommend naltrexone or acamprosate in combination with counseling (Class I, Level A) for patients without liver disease, while emphasizing the unique role of baclofen in cirrhotic patients based on RCT evidence.